Oncology Central

What is the role of axillary lymph node dissection, if any, in breast cancer treatment?


In 2013, more than 230,000 women were predicted to be diagnosed with breast cancer. Approximately 90% of these patients will present without evidence of distant metastases [1].

The management of the axillary lymph nodes has been the subject of intense study and ongoing debate over the past few decades. Presentation of the European Phase III EORTC AMAROS trial results at the 2013 Annual Meeting of the American Society of Clinical Oncology has reignited the heated debate in this area [2].

To view restricted content, please:

Leave A Comment